<DOC>
	<DOC>NCT02204111</DOC>
	<brief_summary>The primary objective of the study is to compare quality of life (QoL) between patients suffering from soft tissue sarcoma, receiving a multidimensional intervention with those receiving standard treatment.</brief_summary>
	<brief_title>Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Diagnosis of advanced or metastatic soft tissue sarcoma Treatment with trabectedin in an inlabel prescription Age at least 18 years (inclusive) at the first visit Patients with a life expectancy of at least 6 months The informed consent form must be signed before any study specific tests or procedures are done Confirmation of the subject's health insurance coverage prior to the first visit Ability to understand and follow studyrelated instructions ECOG PS &gt;2 Estimated life expectancy of less than 6 months Patients with STS not receiving trabectedin Contraindications according to the local SmPC of YondelisÂ® Subject is in custody by order of an authority or a court of law Exclusion periods from other studies or simultaneous participation in other clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g. a close relative) or persons working at the study site Subject is an employee of GWTTUD GmbH or Pharma Mar S.A. Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Palliative Treatment</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Patient Reported Outcome</keyword>
</DOC>